Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia

Prescription Drug User Fee Act action date is September 26, 2024


If approved, KarXT would represent the first new pharmacological approach to treating schizophrenia in several decades


The...

Related Keywords

Gordon Lavigne ,Nasdaq ,Securities Exchange ,Drug Administration ,Karuna Therapeutics Inc ,Schizophrenia Psychosis Action Alliance ,Exchange Commission ,Karuna Therapeutics ,New Drug Application ,Prescription Drug User Fee Act ,Bill Meury ,Psychosis Action ,Negative Syndrome Scale ,Rishi Kakar ,Segal Trials ,Securities Act ,Securities Exchange Act ,Annual Report ,Markets ,